ArticleClinical cancer research : an official journal of the American Association for Cancer Research2018
Neuroblastoma Patients' KIR and KIR-Ligand Genotypes Influence Clinical Outcome for Dinutuximab-based Immunotherapy: A Report from the Children's Oncology Group.
Open access · bronzeAbstract read
In one paragraph
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed, 1 pooled it
5.3field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 1 synthesis or guideline pooled it, 61 citations in OpenAlex.
- Anti-GD2 antibody-containing immunotherapy postconsolidation therapy for people with high-risk neuroblastoma treated with autologous haematopoietic stem cell transplantation.The Cochrane database of systematic reviews · 2019Pooled it
- Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032.Clinical cancer research : an official journal of the American Association for Cancer Research · 2021Trial
- Immunomonitoring of Stage IV Relapsed Neuroblastoma Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplantation and Subsequent GD2 (ch14.18/CHO) Antibody Treatment.Frontiers in immunology · 2021Trial
- Follicular lymphoma patients with KIR2DL2 and KIR3DL1 and their ligands (HLA-C1 and HLA-Bw4) show improved outcome when receiving rituximab.Journal for immunotherapy of cancer · 2019Trial
- Umbilical cord blood natural killer cells improve anti-GD2 antibody efficacy in neuroblastoma: from mouse to human.Oncoimmunology · 2026Article
- Bispecific GD2xB7-H3 Antibody Improves Tumor Targeting and Reduces Toxicity while Maintaining Efficacy for Neuroblastoma.bioRxiv : the preprint server for biology · 2026Article
- Review
- Immunotherapeutic Strategies Targeting GD2-Expressing Malignancies.Advances in experimental medicine and biology · 2026Review
- High-risk neuroblastoma as a model for immunotherapy of non-immunogenic cancers: where might we be in 20 years?Journal for immunotherapy of cancer · 2025Review
- Chromosomal instability degrades developmental phenotypes essential for anti-GD2 immunotherapy outcomes in high-risk neuroblastoma.Cell reports. Medicine · 2025Article
- Phase I Study ofJournal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025Article
- Analysis of Phenotypic and Molecular Variability of Memory-like NK Cells for Cancer Adoptive Cell Therapy Screening.Cancers · 2025Article
- Natural killer cells adopt an activated and decidual-like phenotype after autologous hematopoietic stem cell transplantation in children with cancer.Communications medicine · 2025Article
- Society for Immunotherapy of Cancer (SITC) consensus statement on essential biomarkers for immunotherapy clinical protocols.Journal for immunotherapy of cancer · 2025Article
- Dynamics of NK cell subsets following autologous hematopoietic stem cell transplantation in adult oncologic patients.Frontiers in immunology · 2025Article
- Children's Oncology Group's 2023 blueprint for research: Neuroblastoma.Pediatric blood & cancer · 2023Article
- Associations between KIR/KIR-ligand genotypes and clinical outcome for patients with advanced solid tumors receiving BEMPEG plus nivolumab combination therapy in the PIVOT-02 trial.Cancer immunology, immunotherapy : CII · 2023Article
- KIR/KIR-ligand genotypes and clinical outcomes following chemoimmunotherapy in patients with relapsed or refractory neuroblastoma: a report from the Children's Oncology Group.Journal for immunotherapy of cancer · 2023Article
- Safety and efficacy of dinutuximab in the treatment of neuroblastoma: A review.Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2023Review
- Immunotherapy of Neuroblastoma: Facts and Hopes.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022Review
Corrections and comments
- Commented on by
Authors and funding
23 authors at 13 institutions in 2 countries.
Amy K ErbeDepartment of Human Oncology, University of Wisconsin, Madison, Wisconsin.
Wei WangDepartment of Human Oncology, University of Wisconsin, Madison, Wisconsin.
Lakeesha CarmichaelDepartment of Biostatistics and Medical Informatics, University of Wisconsin, Madison, Wisconsin.
KyungMann KimDepartment of Biostatistics and Medical Informatics, University of Wisconsin, Madison, Wisconsin.
Eneida A MendonçaDepartment of Biostatistics and Medical Informatics, University of Wisconsin, Madison, Wisconsin.
Yiqiang SongDepartment of Biostatistics and Medical Informatics, University of Wisconsin, Madison, Wisconsin.
Dustin HessDepartment of Human Oncology, University of Wisconsin, Madison, Wisconsin.
Patrick K RevilleDepartment of Human Oncology, University of Wisconsin, Madison, Wisconsin.
Wendy B LondonDana-Farber/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School, Boston, Massachusetts.
Arlene NaranjoCOG Statistics and Data Center, Department of Biostatistics, University of Florida, Gainesville, Florida.
Jacquelyn A HankDepartment of Human Oncology, University of Wisconsin, Madison, Wisconsin.
Mitchell B DiccianniDepartment of Pediatrics, Hematology/Oncology and Moores Cancer Center, University of California, San Diego, California.
Ralph A ReisfeldScripps Research Institute, La Jolla, California.
Stephen D GilliesProvenance Biopharmaceuticals, Carlisle, Massachusetts.
Katherine K MatthayUCSF Benioff Children's Hospital and University of California School of Medicine, San Francisco, California.
Susan L CohnDepartment of Pediatrics, University of Chicago, Chicago, Illinois.
Michael D HogartyChildren's Hospital of Philadelphia and University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania.
John M MarisChildren's Hospital of Philadelphia and University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania.
Julie R ParkSeattle Children's Hospital, Seattle, Washington.
M Fevzi OzkaynakNew York Medical College, Valhalla, New York.
Andrew L GilmanLevine Children's Hospital, Charlotte, North Carolina.
Alice L YuDepartment of Pediatrics, Hematology/Oncology and Moores Cancer Center, University of California, San Diego, California.
Paul M SondelDepartment of Human Oncology, University of Wisconsin, Madison, Wisconsin. pmsondel@humonc.wisc.edu.
University of Wisconsin–Madison · USChildren's Hospital of Philadelphia · USChang Gung Memorial Hospital · TWDana-Farber/Boston Children's Cancer and Blood Disorders Center · USLevine Children's Hospital · USNew York Medical College · USscPharmaceuticals (United States) · USScripps Research Institute · USUCSF Benioff Children's Hospital · USUniversity of California San Diego · USUniversity of Florida · USUniversity of Illinois Chicago · USUniversity of Washington · US
Funding
NCTN BIQSFP ANBL1531 (NRT)U10CA180886 · NCI · PUBLIC HEALTH INSTITUTE · PI Douglas S. Hawkins · 2014 to 2026
$390.6MUW COMPREHENSIVE CANCER CENTER SUPPORTP30CA014520 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI Christian Capitini · 1985 to 2026
$142.6MCOG SDMC - Statistics CoreU10CA180899 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI TODD A ALONZO · 2014 to 2026
$132.8MEnhancing Antibody-directed Innate Immunity to Improve Cancer OutcomeR35CA197078 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI SONDEL, PAUL M · 2015 to 2021
$6.4MThe Role of KIR and FcR Genotype in the Efficacy of mAb and IL2 ImmunotherapyR01CA166105 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI SONDEL, PAUL M · 2012 to 2014
$987kPredicting toxicity and success of anti-GD2 immunotherapy of neuroblastomaR01CA164132 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI YU, ALICE L. · 2012 to 2014
$936kNCI NIH HHS P30 CA014520NCI NIH HHS R01 CA164132NCI NIH HHS R01 CA166105NCI NIH HHS R35 CA197078NCI NIH HHS U10 CA180886NCI NIH HHS U10 CA180899
Abstract
PubMed holds no abstract for this paper.
Indexed as
GenotypeAntibodies, MonoclonalAntineoplastic Agents, ImmunologicalCell Line, TumorClinical Trials, Phase III as TopicFemaleHumansImmunotherapyLigandsMaleNeuroblastomaReceptors, KIRReceptors, KIR2DL1Receptors, KIR3DL1Antibodies, MonoclonalAntineoplastic Agents, ImmunologicaldinutuximabKIR2DL1 protein, humanKIR3DL1 protein, humanLigandsReceptors, KIRReceptors, KIR2DL1Receptors, KIR3DL1
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.